EZH2 and myelodysplastic syndrome: It is also one of the pathologic myelodysplasia-related gene mutations that is considered adverse risk in 2022 ELN, and the presence of EZH2 confers a diagnosis of myelodysplastic syndrome/AML rather than myelodysplastic syndrome for patients with ≥10% blasts per Internation Consensus Classification.10